Valerio Therapeutics operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Valerio Therapeutics's Operating Margin % or its related term are showing as below:
XPAR:ALVIO'
s Operating Margin % Range Over the Past 10 Years
Min: -1185.93 Med: -481.83 Max: -21.38
Current: -21.38
XPAR:ALVIO's Operating Margin % is ranked better than 62.86% of 945
companies
in the Biotechnology industry
Industry Median: -86.77
vs XPAR:ALVIO: -21.38
Valerio Therapeutics's 5-Year Average Operating Margin % Growth Rate was 23.80% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Valerio Therapeutics Operating Margin % Related Terms
Valerio Therapeutics Operating Margin % Historical Data
* Premium members only.
The historical data trend for Valerio Therapeutics's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALVIO vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Valerio Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valerio Therapeutics Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Valerio Therapeutics's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Valerio Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valerio Therapeutics (XPAR:ALVIO) has a Operating Margin % of -25.62% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Valerio Therapeutics and its competitors. According to the industry distribution chart, Valerio Therapeutics ranks #351 out of 945 companies in the Biotechnology industry, placing it in the top 37.1%.
Is Valerio Therapeutics' Operating Margin % too high?
Valerio Therapeutics' current Operating Margin % is -25.62%. Based on the distribution chart, Valerio Therapeutics ranks #351 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Valerio Therapeutics has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Valerio Therapeutics' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valerio Therapeutics ranks #351 out of 945 companies for Operating Margin %. This puts Valerio Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Valerio Therapeutics and its competitors. Valerio Therapeutics's current Operating Margin % is -25.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valerio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Valerio Therapeutics (XPAR:ALVIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.07, compared to a current price of €0.20 — trading 184.6% above its estimated fair value. The current Operating Margin % is -25.62%. Valerio Therapeutics' overall GF Score™ is 25/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Valerio Therapeutics (XPAR:ALVIO), the current Operating Margin % is -25.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valerio Therapeutics (XPAR:ALVIO) Overvalued in 2026?
Based on GuruFocus' analysis, Valerio Therapeutics stock appears to be overvalued.
The current stock price of €0.20 is trading 184.6% above its estimated GF Value™ of €0.07.
GuruFocus considers Valerio Therapeutics to be Significantly Overvalued.
Key valuation signals for XPAR:ALVIO:
Operating Margin %: -25.62%
GF Value™: €0.07 vs. price of €0.20 (184.6% above fair value)
No single metric tells the full story. See the XPAR:ALVIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
25GF Score
Get the complete analysis for XPAR:ALVIO
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALVIO has been successfully added to your 
